✨ Free AI Report
Shattuck Labs, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Shattuck Labs, Inc.
Company Research

Shattuck Labs, Inc.: Business Overview, Financials & Competitive Analysis

Shattuck Labs, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). DR3 pathway validation at the clinic with multi-year runway offers steady-state risk/reward in a validated immunology market. The company achieved IND clearance for SL-325 in August 2025 with first participants dosed in Phase 1 in Q3 2025, with enrollment expected complete by Q2 2026 and initial data expected by.

What is Shattuck Labs, Inc.'s industry? Shattuck Labs, Inc. (shattucklabs.com) operates in Biopharmaceuticals / Clinical-Stage Immunology. AskCyborg classifies Shattuck Labs, Inc. under Biopharmaceuticals / Clinical-Stage Immunology in its company registry.

Shattuck Labs is a biotechnology company developing antibodies for the treatment of inflammatory and immune-mediated diseases. The company is pioneering the development of potentially first-in-class monoclonal and bis...

6/ 10Solid

Cyborg Score thesis

DR3 pathway validation at the clinic with multi-year runway offers steady-state risk/reward in a validated immunology...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Clinical-Stage Immunology
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Shattuck Labs, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Shattuck Labs, Inc.

AskCyborg analysts argue the bull and bear cases for Shattuck Labs, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Shattuck Labs, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Shattuck Labs, Inc. Overview

Pro stress-test →

Shattuck Labs is a biotechnology company developing antibodies for the treatment of inflammatory and immune-mediated diseases. The company is pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies. As a clinical-stage biotech with $86M in cash (Q3 2025), Shattuck is advancing its lead candidate SL-325 through Phase 1 trials targeting inflammatory bowel disease (IBD).

Strategic Profile

Pro stress-test →

The company's lead asset SL-325 is being advanced through multiple Phase 2 clinical trials focusing on Inflammatory Bowel Disease (IBD). Shattuck closed a private placement of up to $103 million in August 2025 expected to fund operations into 2029. The company is strategically positioned in the high-potential TNF superfamily receptor pathway with experienced leadership additions from J&J/Janssen and OrbiMed.

Competitive Landscape

Pro stress-test →

Shattuck competes in the immunology/IBD therapeutics space against major pharma (Janssen, Gilead, AbbVie) and emerging biotech (Foghorn Therapeutics, C4 Therapeutics). Its differentiation rests on the first-in-class DR3 mechanism and bispecific platform enabling combination potential. Market size and clinical validation of TNF pathways provide tailwinds.

Industry Context

Shattuck Labs, Inc. operates in Biopharmaceuticals / Clinical-Stage Immunology.

Key facts

Founded: 2016 · Headquarters: Austin, US · Employees: 44 · Market cap: $286.66M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Shattuck Labs, Inc..

  • IND effective for SL-325 (August 2025) with Phase 1 enrollment on track for Q2 2026 data readout
  • Well-capitalized through 2029 with $86.1M cash post-private placement; net loss narrowing ($10.1M in Q3 2025)
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced participation in TD Cowen and Leerink March 2026 healthcare conferences
  • December 2025Granted inducement equity awards to newly hired non-executive officer
  • +2 moreTrack every material event for Shattuck Labs, Inc. as it happens. Explore monitoring →
Get alerted when Shattuck Labs, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Foghorn Therapeutics (FHTX)Protein degradation platform for cancer and immunology→C4 Therapeutics (CCCC)E3 ligase-directed protein degradation platform→Janssen/J&J IBD PortfolioEstablished TNF and integrin inhibitor-based IBD therapies→Gilead/Galapagos FilgotinibJAK inhibitor for moderate-to-severe IBD→

Compare Shattuck Labs, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Shattuck Labs, Inc. operates in Biopharmaceuticals / Clinical-Stage Immunology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Clinical-Stage Immunology research →
NEW · MCP server

Ask your AI assistant about Shattuck Labs, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Shattuck Labs, Inc. and its top competitor on Cyborg Score”
“What did Shattuck Labs, Inc. do this quarter?”
“Is Shattuck Labs, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Shattuck Labs, Inc. do?+
Shattuck Labs is a biotechnology company developing antibodies for the treatment of inflammatory and immune-mediated diseases. The company is pioneering the development of potentially first-in-class monoclonal and bis...
What is Shattuck Labs, Inc.'s Cyborg Score?+
Shattuck Labs, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Shattuck Labs, Inc.'s main competitors?+
Named competitors include Foghorn Therapeutics (FHTX), C4 Therapeutics (CCCC), Janssen/J&J IBD Portfolio, Gilead/Galapagos Filgotinib. The full competitive landscape is in the AskCyborg report.
How can I get the full Shattuck Labs, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Shattuck Labs, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Shattuck Labs, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score